Puma Biotechnology Inc. (PBYI)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why
PBYI's shares rally 19% in three months as rising Nerlynx demand and a raised 2026 revenue outlook boost investor confidence.
Puma Biotechnology Q1 Earnings Call Highlights
Puma Biotechnology NASDAQ: PBYI reported first-quarter 2026 total revenue of $44.8 million, driven primarily by NERLYNX product revenue net of $42.0 million and royalty revenue of $2.8 million, according to remarks on the company's earnings call. Management attributed the quarter's product revenue performance in part to a specialty pharmacy and distributor inventory drawdown and highlighted new interim clinical data from ongoing Phase II alisertib studies in small cell lung cancer and HER2-negative, hormone receptor-positive breast cancer.
PBYI Q1 Earnings & Sales Beat Estimates, 2026 Guidance Raised
Puma Biotechnology beats Q1 earnings and revenue estimates while raising its 2026 outlook.
Puma Biotechnology Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 293 | $1,583.8 | $2,443.5 | $859.7 | 54.28% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 500 | $3,195 | $4,150 | $955 | 29.89% |
 Joseph Castro Nuveen LLC | 79,101 | $234,139 | $668,007.94 | $433,868.94 | 185.3% |
 Kimberly Cappellano Private Wealth Asset Management LLC | 3,500 | $11,065 | $29,557.5 | $18,492.5 | 167.13% |
 Jennifer Grunberg Allspring Global Investments Holdings LLC | 17,066 | $109,051.74 | $144,378.36 | $35,326.62 | 32.39% |
Puma Biotechnology Inc. (PBYI) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Puma Biotechnology Inc. ever had a stock split?
Puma Biotechnology Inc. Profile
| Biotechnology Industry | Healthcare Sector | Alan H. Auerbach CEO | NASDAQ (NGS) Exchange | 74587V107 CUSIP |
| US Country | 179 Employees | - Last Dividend | - Last Split | 24 Apr 2012 IPO Date |
Overview
Puma Biotechnology, Inc. is a biopharmaceutical company with a sharp focus on the development and commercialization of innovative products aimed at improving cancer care, both within the United States and globally. Since its establishment in 2010, the company has been dedicated to bringing forward novel therapies that cater to specific cancer care needs. With headquarters in Los Angeles, California, Puma Biotechnology has built a strong presence in the oncology space through its strategic license agreements for the development, manufacture, and commercialization of key compounds with leading pharmaceutical companies such as Pfizer Inc. and Takeda Pharmaceutical Company Limited. Moreover, the company extends its market reach through sub-license agreements with several international pharmaceutical companies, facilitating the global distribution of its oncology products.
Products and Services
-
NERLYNX (neratinib, oral)
This is an oral medication developed by Puma Biotechnology, designed specifically for the treatment of adult patients who are dealing with early-stage HER2-overexpressed/amplified breast cancer. In addition, NERLYNX, when combined with capecitabine, is indicated for patients suffering from advanced or metastatic HER2-positive breast cancer. This highlights the company's dedication to providing targeted therapies for patients with specific cancer types, offering them a chance for a better quality of life and improved treatment outcomes.
-
Alisertib (small molecule inhibitor of aurora kinase A)
Currently under development, alisertib represents Puma Biotechnology's commitment to expanding its oncology portfolio. This small molecule inhibitor targets aurora kinase A, a protein associated with cellular division and is implicated in various types of cancer. Puma Biotechnology is exploring alisertib's potential in treating hormone receptor-positive breast cancer, triple-negative breast cancer, small cell lung cancer, and head and neck cancer. This signifies the company's investment in broadening the scope of its research and development efforts to encompass a wider array of cancer types, aiming to fill therapy gaps and meet the diverse needs of cancer patients.
